Expert Interview
A Second Opinion: An updated look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker(s): VRTXInstitution: Trinity Health IHA Medical Group
- Board-certified in pulmonary and internal medicine and board-eligible in critical care
- Clinical interests include interstitial lung disease, lung cancer screening, and cystic fibrosis
- Published several publications and presented at numerous pulmonary and critical care conferences.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
